The UK has granted the world’s first approval for a Covid-19 vaccine targeting a variant in a bid to sharpen its response to an evolving coronavirus.
The country’s Medicines and Healthcare products Regulatory Agency cleared
Moderna’s bivalent shot targets two strains - half of the dose works against the original version of the coronavirus, while the other half protects against BA.1, an early version of the omicron variant that fueled ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.